The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy

Authors

  • Dr. Robert D. Loberg PhD,

    1. Loberg is Research Assistant Professor, Internal Medicine and Urology, University of Michigan, Ann Arbor, MI
    Search for more papers by this author
  • Dr. Deborah A. Bradley MD,

    1. Bradley is Fellow, Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI
    Search for more papers by this author
  • Mr. Scott A. Tomlins,

    1. Tomlins is Graduate Student, Department of Pathology, University of Michigan, Ann Arbor, MI
    Search for more papers by this author
  • Dr. Arul M. Chinnaiyan MD, PhD,

    1. Chinnaiyan is S. P. Hicks Endowed Professorship; Professor of Pathology and Urology; Director of Pathology Research Informatics; and Director of Cancer Bioinformatics, University of Michigan, Ann Arbor, MI
    Search for more papers by this author
  • Dr. Kenneth J. Pienta MD

    1. Pienta is Professor, Internal Medicine and Urology; and American Cancer Society Clinical Research Professor, University of Michigan, Ann Arbor, MI.
    Search for more papers by this author

Abstract

The last decade has seen an explosion in knowledge of the molecular basis and treatment of cancer. The molecular events that define the lethal phenotype of various cancers—the genetic and cellular alterations that lead to a cancer with a poor or incurable prognosis—are being defined. While these studies describe the cellular events of the lethal phenotype of cancer in detail, how these events result in the common clinical syndromes that kill the majority of cancer patients is not well understood. It is clear that the central step that makes most cancers incurable is metastasis. Understanding the traits that a cancer acquires to successfully grow and metastasize to distant sites gives insight into how tumors produce multiple factors that result in multiple different clinical syndromes that are lethal for the patient.

Ancillary